Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome

Globe Newswire December 18, 2013

Alcobra Ltd. Announces Highly Statistically Significant Positive Phase IIb Clinical Trial Results in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

Globe Newswire December 16, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ADHD, BLUE, STML and XLRN

Accesswire December 11, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on ADHD, CCXI, FLEX and NTAP

Accesswire December 5, 2013

Alcobra to Present at the 25th Annual Piper Jaffray Healthcare Conference

Globe Newswire December 2, 2013

Alcobra Ltd. Announces New Findings on Diminished Abuse Potential of Its Proprietary Drug Candidate, MG01CI

Globe Newswire November 22, 2013

Alcobra Successfully Completes Enrollment in Comparative Phase II Study of Attention and Cognitive Function Benefits in Patients With PI-ADHD

Globe Newswire November 5, 2013

Alcobra Ltd. to Host a Third Quarter 2013 Conference Call on November 7th

Globe Newswire October 31, 2013

Alcobra Ltd. Announces Closing of Approximately $38 Million Public Offering of Ordinary Shares

Globe Newswire October 30, 2013

Alcobra Ltd. Announces Full Exercise of Over-Allotment Option by Underwriters

Globe Newswire October 29, 2013

Alcobra Ltd. Prices Public Offering of $33 Million of Ordinary Shares

Globe Newswire October 24, 2013

Alcobra Ltd. to Present at AACAP's 60th Annual Meeting on October 24th

Globe Newswire October 21, 2013

Alcobra Ltd. Announces New Findings on Novel Mechanism of Action for its Proprietary Drug, MG01CI, for Treatment of Cognitive Dysfunctions

Globe Newswire October 14, 2013

Alcobra Ltd. Selects CNS Clinical Trials Expert Premier Research as CRO for Phase III Clinical Study of MG01CI as a Treatment for Adults With ADHD

Globe Newswire October 2, 2013

Alcobra to Present Fragile X Study Results at 2013 FRAXA Investigators Meeting

Globe Newswire September 25, 2013

LifeSci Advisors Initiates Coverage of Alcobra Ltd.

Marketwired September 23, 2013

Alcobra Ltd. to Present at the Aegis Capital 2013 Annual Healthcare Conference on September 26th in Las Vegas

Globe Newswire September 19, 2013

Alcobra's Pre-Clinical Fragile X Study for MG01CI Shows Significant Positive Results

Globe Newswire September 10, 2013

Alcobra Ltd. to Present at the Stifel Nicolaus 2013 Annual Healthcare Conference on September 11th

Globe Newswire September 3, 2013

Alcobra Enrolls First Patient in Comparative Study of Executive Function Benefits in Patients With PI-ADHD

Globe Newswire August 26, 2013